Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
180 participants
OBSERVATIONAL
2024-11-04
2025-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Entia Liberty: Capillary Validation
NCT05025111
Entia Liberty: Accuracy and Precision
NCT05025124
Entia Liberty: Home Study
NCT05462288
Lymphedema Sensor Technology Development Study
NCT06778837
Blood Testing at Entia
NCT05580055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1
Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.0 x109/L who can be consented within 24 hours of the result.
Participants will donate one finger prick sample up to once per day to be tested on the Liberty device.
Entia Liberty System
Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
Phase 2
Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.5 x109/L who can be consented within 24 hours of the result.
Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session.
Entia Liberty System
Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
Phase 3
Participants who are undergoing a routine venous draw as part of the standard of care as part of SACT toxicity monitoring.
Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session.
Entia Liberty System
Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Entia Liberty System
Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing systemic anti-cancer therapy (SACT)
* Patients capable of providing written informed consent
* Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care
* Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
* Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting
Exclusion Criteria
* Inadequate use and understanding of the English language, requiring a translator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Entia Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Madeline Lok
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
347665
Identifier Type: OTHER
Identifier Source: secondary_id
CTM-PRO-00028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.